Action Antibe Therapeutics - ATE

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,405

Prix Achat

0,405

Prix Vente

0,41

Volume échangé

0,00 Fourchette du Jour 0,00

0,405 Plage de 52 semaines 0,405

Clôture Veille

0,405

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual...

Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Inc.: - Phase II secondary data confirmed remarkable potency of ATB-346 - - 3rd party commercial studies project peak...

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain - - ATB-346 is more potent than expected; lowest effective...

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain...

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th...

Antibe Therapeutics Announces Upcoming Conference Schedule

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and...

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week...

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the fourth quarter...

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) will be front-and-centre at the 4th International Conference on the Biology of...

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral & Maxillofacial...

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.405	0.405	0.405	0	0	CS
4	0	0	0.405	0.405	0.405	0	0	CS
12	0	0	0.405	0.405	0.405	0	0	CS
26	0	0	0.405	0.405	0.405	0	0	CS
52	0	0	0.405	0.405	0.405	0	0	CS
156	0	0	0.405	0.405	0.405	0	0	CS
260	-0.275	-40.4411764706	0.68	0.89	0.305	191019	0.52982942	CS

ATE - Frequently Asked Questions (FAQ)

What is the current Antibe Therapeutics share price?

The current share price of Antibe Therapeutics is $ 0,405

What is the 1 year trading range for Antibe Therapeutics share price?

Antibe Therapeutics has traded in the range of $ 0,405 to $ 0,405 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
KUR.HKure Technologies Inc	$ 0,10 (233,33%)	1 000
BYM.HBaymount Incorporated	$ 0,015 (200,00%)	1 000
OVL.HOlivier Ventures Inc	$ 0,015 (200,00%)	55,1k
AGH.HCanadian Silver Hunter Inc	$ 0,04 (100,00%)	2k
WT.HWangton Capital Corp	$ 0,04 (100,00%)	1,5k
SEVSpectra7 Microsystems Inc	$ 0,025 (-58,33%)	826,85k
PORPortofino Resources Inc	$ 0,005 (-50,00%)	126k
CLMConsolidated Lithium Metals Inc	$ 0,005 (-50,00%)	2k
JHCJinhua Capital Corporation	$ 0,025 (-50,00%)	228k
ECAP.PEndurance Capital Corp	$ 0,025 (-37,50%)	1 000
SPCSPC Nickel Corp	$ 0,025 (66,67%)	2,11M
SLGSan Lorenzo Gold Corp	$ 0,30 (-6,25%)	2,11M
PERPeruvian Metals Corp	$ 0,025 (25,00%)	1,71M
FMNFidelity Minerals Corporation	$ 0,04 (0,00%)	1,64M
BYNBanyan Gold Corp	$ 0,23 (4,55%)	1,59M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Antibe Therapeutics Inc (ATE)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

ATE Dernières nouvelles

Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Announces Upcoming Conference Schedule

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral & Maxillofacial...

ATE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Antibe Therapeutics Inc (ATE) Cours

Antibe Therapeutics Inc (ATE)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

ATE Dernières nouvelles

Antibe Therapeutics to Present at Upcoming Conferences

Antibe Therapeutics Provides Corporate Update

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346

Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Announces Upcoming Conference Schedule

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral & Maxillofacial...

ATE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités